Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Axantia Group","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intas and Axantia Sign an Exclusive License and Supply Agreement for Ranibizumab Biosimilar in the Middle East","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"JORDAN","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Axantia Group

    Menu

    Axantia Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Axantia Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Jordan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Intas and Axantia Sign an Exclusive License and Supply Agreement for Ranibizumab Biosimilar in the Middle East

              Details:

              Under the terms of this agreement, Axantia will register, hold the marketing authorization and commercialize Ranibizumab in certain territories including Saudi Arabia, Jordan, Iraq, Lebanon and GCC countries.

              Lead Product(s): Ranibizumab

              Therapeutic Area: Ophthalmology Product Name: Razumab

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Intas Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY